Loading company
Alnylam Pharmaceuticals, Inc.
ALNY · Nasdaq · Healthcare · Biotechnology
Next earnings: October 29, 2026
$254.04-0.5%Sep 29 close
- 1M
- +7.1%
- 6M
- -19.6%
- 1Y
- -44.3%
- 5Y
- +31.0%
ALNY · Nasdaq · Healthcare · Biotechnology
Next earnings: October 29, 2026
$254.04-0.5%Sep 29 close
Alnylam Pharmaceuticals, Inc. is scheduled to report next on October 29, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toMar 31, 2025 | Change |
|---|---|---|---|
| Total Revenue | $1.3B | $594.2M | +117.26% |
| Profit | $164.5M | -$72.2M | +327.74% |
| Profit per share | $1.21 | -$0.14 | +964.29% |
| Free Cash Flow | $140.3M | -$103.8M | +235.19% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Releases land after the close or before the open, so the move is the session that follows.
Technology Alnylam has licenses to Arbutus Biopharma lipid nanoparticle (LNP) intellectual property for use in RNAi therapeutic products using LNP technology.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Alnylam Pharmaceuticals, Inc.’s Item 2.02 8-K filed July 30, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
A short summary of each call — what the quarter showed, what management expects and whether they delivered on what they said last time — with the full transcript underneath.
Source: Yahoo Finance, transcribed by Quartr. Speaker names and roles are as transcribed; analysts are sometimes unnamed.
Summaries of earlier calls are part of Pro.
Summaries of earlier calls are part of Pro.
Summaries of earlier calls are part of Pro.
Call summaries are part of Pro
A two-minute read of every Alnylam Pharmaceuticals, Inc. earnings call: the numbers that mattered, what management expects, whether they delivered on last quarter’s outlook, and what analysts asked that went unanswered.
See one first on , , or — open to everyone.
Summaries of earlier calls are part of Pro.
Summaries of earlier calls are part of Pro.